5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

A Busy 2019 ends with a quiet December

January 10, 2020
-
Market Access News
-
Posted by MORSE - 2 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights

 

The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations.  Highlights since the last update include:

  • 3 products completed CADTH review, for a total of 10 files under consideration;
  • 0 products initiated pCPA negotiations, for a total of 32 active negotiations;
  • 1 negotiation completed for a total of 295 completed negotiations;
  • 1 negotiation closed, for a total of 48 closed negotiations; and
  • 1 file closed without negotiations, for a total of 73 declined negotiations.

  

Files Under pCPA Consideration

 

3 new drug products received a CDEC recommendation or pERC notification to implement in December 2019, for a total of approximately 10 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Tegsedi* Inotersen Akcea Therapeutics Hereditary Transthyretin Amyloidosis Conditional
Lynparza Olaparib AstraZeneca Ovarian Cancer Conditional
Nerlynx Neratinib Knight Therapeutics Hormone Receptor Positive Breast Cancer
Does not recommend

*While this file received a CADTH recommendation in December, Tegsedi commenced negotiations in November 2019 following an August 2019 INESSS recommendation and therefore, has not been counted as an under-consideration file.

 

Signals Decoded:
 
Lynparza, which is already widely reimbursed as a maintenance treatment option in ovarian cancer, receives a conditional recommendation for use in newly diagnosed ovarian cancer. Tegsedi, which had negotiations initiated in November 2019, receives a conditional recommendation from CADTH.

 

 

Completed

 

The pCPA completed 1 negotiation since the last update for a total of 295 completed negotiations.

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Prevymis Letermovir Merck Prevention of Cytomegalovirus Infection Nov 2018 395 days

 

Closed

The pCPA closed 1 negotiation since the last update for a total of 48 closed negotiations.

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Lutathera Lutetium Lu-177 Advanced Accelerator Applications Midgut Neuroendocrine Tumours Sep 2019 91 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

Signals Decoded:

Of the 32 active negotiations, the 18 non-oncology files have been under active negotiation for an average of 235 calendar days as of December 15, 2019 (range: 30 to 944 days). The remaining 14 oncology files have been under active negotiation for an average of 201 calendar days as of December 15, 2019. (range: 30 to 487 days).

 

 

Not Negotiated

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Decision*
Vitrakvi Larotrectinib Bayer Locally Advanced or Metastatic Solid Tumors that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion 15 Nov 19 30 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
MORSE Consulting Releases its Third Annual pCPA Year in Review Infographic (2019 Edition)
NEXT POST →
Season’s Greetings from MORSE Consulting

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
A Busy 2019 ends with a quiet December